ArticleBrain pathology (Zurich, Switzerland)2026
Complement receptor C3aR marks heterogeneous tumor-associated macrophage states associated with improved survival in IDH-wildtype glioblastoma.
Article in Brain pathology (Zurich, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioblastomas (GBM), IDH-wildtype, are highly aggressive brain tumors with poor prognosis and inter-individual variability despite established prognostic factors such as age, performance status, and MGMT promoter (MGMTp) methylation. Increasing evidence highlights the role of the tumor microenvironment (TME) in GBM progression. The complement system, a key component of innate immunity, can influence tumor growth and immune regulation through the generation of the anaphylatoxin C3a and the activation of its receptor, C3aR. While C3a/C3aR signaling has been associated with various outcomes in several malignancies, its prognostic relevance in GBM remains poorly defined. This study investigated the expression of C3aR in human IDH-wildtype GBM and its association with clinicopathological features and overall survival. We retrospectively analyzed a cohort of 114 patients with IDH-wildtype GBM. C3aR expression was assessed by immunohistochemistry and quantified using digital image analysis. C3aR expression was analyzed as a categorical variable using an outcome-derived cutpoint (C3aR-high and C3aR-low) for exploratory purposes. Associations with clinical variables, including MGMTp methylation status, were evaluated. C3aR expression showed marked inter-tumoral heterogeneity and was enriched among MGMTp-methylated tumors (p = 0.004). Patients with C3aR-high tumors exhibited improved overall survival (log-rank p = 0.033). In a multivariable Cox regression model including age, performance status, surgery type, and MGMTp methylation status, high C3aR expression remained independently associated with improved overall survival (HR 0.50, 95% CI 0.29-0.87, p = 0.014). Tissue-based and single-cell analyses supported the association of C3aR with the myeloid/macrophage compartment and heterogeneous macrophage phenotypes. These findings support a relationship between C3aR expression and the heterogeneous macrophage landscape of IDH-wildtype GBM, while the survival association remains exploratory and requires independent validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.